Lung cancer patient finds pain relief at MD Anderson
“It may seem strange to feel lucky while going through cancer treatment, but that’s exactly how I feel. My lung cancer experience hasn’t been easy, but thanks to a few strokes of luck, including finding a successful treatment plan at MD Anderson, I’m feeling well and enjoying life.”
Unraveling the mystery of who gets lung cancer and why
“Why do some heavy smokers never get lung cancer? And why do some people who never smoke get lung cancer? Answers are emerging for both of those questions. In both cases, much depends on our individual genetic make-up.”
UCLA receives grant to improve liquid biopsy for early lung cancer detection
“A team of investigators from the UCLA Jonsson Comprehensive Cancer Center and the UCLA School of Dentistry received a five-year $4.6 million grant from the National Cancer Institute to develop and improve liquid biopsy technologies for the early detection of lung cancer -; the leading cause of cancer death in both men and women in the U.S.”
Higher Rates of Lung Cancer in Women Are a Mystery for Researchers
“(CNN) — More young and middle-aged women are being diagnosed with lung cancer at a higher rate than men, and scientists are struggling to understand why, new research shows. Awareness of the disease’s effects on women is lacking, experts say, and the U.S. government spends significantly less on its research than on similar studies in men.”
FDA Clears Pfizer’s Braftovi + Mektovi for Non-Small Cell Lung Cancer Treatment
“Pfizer revealed that the FDA has approved Braftoni (encorafenib) + Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. Previously, the medication was approved for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation.”
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
“RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) met its dual primary endpoint of overall survival (OS).”
Video:
“Bright Future of Lung Cancer Research: Targeted Therapies and Immunotherapy Advancements”
